Minerva Neurosciences publishes corporate presentation on roluperidone for schizophrenia negative symptoms

• Minerva Neurosciences highlighted roluperidone as a potential first treatment for primary negative symptoms of schizophrenia, an area with no FDA-approved therapies.
• The company said roluperidone showed meaningful improvement in negative symptoms in two registrational trials, C03 and C07, with C07 meeting the negative-symptom endpoint on a nominal basis.
• A confirmatory Phase 3 trial, C19, is actively enrolling, with topline 12-week efficacy data expected in 2H 2027; the study targets about 380 patients across about 40 sites in the U.S. and four European countries.
• Minerva cited a USD 200 million financing led by Vivo Capital in October 2025, stating it fully funds the program through C19 data and an NDA submission.
• The deck pegged the U.S. schizophrenia drugs market at about USD 4.2 billion in 2025, with roluperidone peak annual net sales potential estimated at more than USD 2 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein.